Shin Seong Hwan, Park Sung Pyo, Kim Yong Kyu
Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
Korean J Ophthalmol. 2018 Jun;32(3):196-203. doi: 10.3341/kjo.2017.0081. Epub 2018 May 15.
To investigate factors associated with pain intensity following intravitreal injection and factors that might be associated with changes in pain intensity in patients who received repeated injections.
A total of 172 eyes (147 patients) were prospectively enrolled. Patients rated their pain from 0 to 10 using a visual analogue scale. Multiple linear regression analysis was used to evaluate factors associated with pain score. Sixty-eight patients evaluated their degree of pain more than once and were divided into three groups according to changes in pain during repeated injections. Clinical factors were compared among the three groups.
Pain scores of women (women, 3.1 ± 1.5 vs. men, 2.4 ± 1.2; p = 0.003), those who received dexamethasone implant injection (dexamethasone implant, 3.5 ± 1.1 vs. anti-vascular endothelial growth factor, 2.7 ± 1.4; p = 0.028), and those who did not undergo anterior chamber paracentesis (ACP) (ACP, 2.6 ± 1.3 vs. no ACP, 3.0 ± 1.6; p = 0.047) were significantly higher than those of the other groups. On multiple linear regression analysis, only female sex and ACP were significantly associated with degree of pain. The waiting time during the second injection was significantly associated with change in degree of pain in patients who received repeated injections.
Women were more prone to perceive pain, and the ACP procedure reduced pain during intravitreal injections. Most patients who received repeated injections felt that pain was similar or decreased compared to that experienced during the previous injection. However, increased waiting time might have been associated with increased discomfort for patients who received repeated injections.
探讨玻璃体内注射后疼痛强度相关因素以及与接受重复注射患者疼痛强度变化可能相关的因素。
前瞻性纳入172只眼(147例患者)。患者使用视觉模拟量表从0至10对疼痛进行评分。采用多元线性回归分析评估与疼痛评分相关的因素。68例患者不止一次评估疼痛程度,并根据重复注射期间疼痛变化分为三组。比较三组间的临床因素。
女性(女性,3.1±1.5 vs.男性,2.4±1.2;p = 0.003)、接受地塞米松植入物注射者(地塞米松植入物,3.5±1.1 vs.抗血管内皮生长因子,2.7±1.4;p = 0.028)以及未行前房穿刺(ACP)者(ACP,2.6±1.3 vs.未行ACP,3.0±1.6;p = 0.047)的疼痛评分显著高于其他组。多元线性回归分析显示仅女性性别和ACP与疼痛程度显著相关。第二次注射时的等待时间与接受重复注射患者的疼痛程度变化显著相关。
女性更易感知疼痛,ACP操作可减轻玻璃体内注射时的疼痛。大多数接受重复注射的患者感觉与前次注射相比疼痛相似或减轻。然而,等待时间延长可能与接受重复注射患者的不适感增加有关。